Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GDC-3280 in Healthy Subjects
NCT02471859Phase 1Completed
- Sponsor
- Genentech
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AK3280 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Genentech. Primary endpoint: Number of participants experiencing an adverse event up to 6 months. Started Jun 2015; status: completed.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02471859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471859.